Trial Profile
A Double-blind, Randomized, Placebo-controlled, Parallel, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Moderate To Severe Ulcerative Colitis (Turandot)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ontamalimab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms TURANDOT
- Sponsors Pfizer
- 02 Mar 2020 Patients (n=440) were included from this and NCT01276509 studies in the PK and pharmacodynamic analyses based on the PK population of the trials published in the Journal of Clinical Pharmacology
- 24 Oct 2018 Brazil, Croatia, Denmark, Norway, Sweden, Switzerland, United Kingdom were the planned locations for this study.
- 24 Oct 2018 Results assessing pharmacodynamic and efficacy biomarkers presented at the 26th United European Gastroenterology Week